AzTrials
AzTrials

Depressive Disorder, MajorPhase 3NCT02709746

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 124 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD). Read more about this study

Who is it for?
Ages 12 to 17 years
Conditions the study is for
Depressive Disorder, Major
What is being tested?
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
784 participants
Where
124 sitesin 19 countries
Study dates
May 2016to 30 Jul 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study).
  • The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™.
  • The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.
  • The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline
  • The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.

Who cannot join

  • The patient has participated in a clinical study <30 days prior to the Screening Visit.
  • Other protocol defined inclusion and exclusion criteria may apply

Trial locations and contacts

124 sites in 19 countries.

124 sites in 19 countries

United States42 sites
  • US1009

    Atlanta, Georgia

  • US1328

    Austin, Texas

  • US1015

    Baltimore, Maryland

  • US1312

    Berlin, New Jersey

  • US1051

    Cincinnati, Ohio

  • US1054

    Cleveland, Ohio

  • US1385 Ericksen Research And Development

    Clinton, Mississippi

  • US1062

    Costa Mesa, California

  • US1064

    Creve Coeur, Missouri

  • US1369

    Dothan, Alabama

  • US1387

    Downey, California

  • US1114

    Escondido, California

  • US1217

    Gainesville, Florida

  • US1118

    Glendale, California

  • US1123

    Imperial, California

  • US1261

    Lake Charles, Louisiana

  • US1310

    Little Rock, Arkansas

  • US1160 Renew Behavioral Health, Inc.

    Long Beach, California

  • US1313

    Marietta, Georgia

  • US1334

    Middleburg Heights, Ohio

  • US1311

    Naperville, Illinois

  • US1315

    Naperville, Illinois

  • US1317

    New York, New York

  • US1314

    O'Fallon, Missouri

  • US1103

    Oak Brook, Illinois

  • US1323

    Oklahoma City, Oklahoma

  • US1329

    Oklahoma City, Oklahoma

  • US1368

    Orange, California

  • US1229

    Orange City, Florida

  • US1308

    Orem, Utah

  • US1370

    Panorama City, California

  • US1320

    Plano, Texas

  • US1222

    Princeton, New Jersey

  • US1309

    Richmond, Virginia

  • US1171

    Rochester, New York

  • US1266

    Saint Charles, Missouri

  • US1162

    San Antonio, Texas

  • US1190

    Staten Island, New York

  • US1333

    Tucson, Arizona

  • US1133

    Washington D.C., District of Columbia

  • US1386

    Wichita, Kansas

  • US1351

    Wildomar, California

Other trials in United States

Russia14 sites
  • RU1009

    Arkhangelsk

  • RU1059

    Engel's

  • RU1046

    Krasnodar

  • RU1011

    Lipetsk

  • RU1004

    Nizhny Novgorod

  • RU1010

    Novosibirsk

  • RU1012

    Rostov-on-Don

  • RU1044

    Rostov-on-Don

  • RU1030

    Saint Petersburg

  • RU1013

    Saratov

  • RU1038

    Saratov

  • RU1057

    Tomsk

  • RU1048

    Tonnel'nyy

  • RU1016

    Yekaterinburg

Other trials in Russia

Italy7 sites
  • IT1075

    Cagliari

  • IT1073

    Genova

  • IT1029

    Messina

  • IT1068

    Naples

  • IT1074

    Padova

  • IT1070

    Pisa

  • IT1072 Osppedale Bambin gesu

    Rome

Other trials in Italy

Mexico7 sites
  • MX1014

    Culiacán

  • MX1011

    Guadalajara

  • MX1013

    Guadalajara

  • MX1022

    Guadalajara

  • MX1023

    Mazatlán

  • MX1003

    Mexico City

  • MX1001

    Nuevo León

Other trials in Mexico

Poland7 sites
  • PL1002

    Bialystok

  • PL1050

    Gdansk

  • PL1068

    Kielce

  • PL1057

    Lublin

  • PL1052

    Poznan

  • PL1054

    Wąbrzeźno

  • PL1051

    Wroclaw

Other trials in Poland

Germany5 sites
  • DE1078

    Freiburg im Breisgau

  • DE1034

    Mainz

  • DE1077

    Mannheim

  • DE1081

    Maulbronn

  • DE1076

    Tübingen

Other trials in Germany

Serbia5 sites
  • RS1006 Clinic of Neurology and Psychiatry for Children and Adolescents

    Belgrade

  • RS1010

    Belgrade

  • RS1011

    Kragujevac

  • RS1003

    Niš

  • RS1007

    Novi Sad

Other trials in Serbia

Spain5 sites
  • ES1041

    Alcorcón

  • ES1044

    Madrid

  • ES1043

    Pamplona

  • ES1018 Hospital de Sabadell

    Sabadell

  • ES1040

    Torremolinos

Other trials in Spain

Colombia4 sites
  • CO1003

    Barranquilla

  • CO1001

    Bello

  • CO1004

    Bogotá

  • CO1002

    Pereira

Other trials in Colombia

Latvia4 sites
  • LV1002

    Jelgava

  • LV1008

    Liepāja

  • LV1009

    Riga

  • LV1007

    Sigulda

Other trials in Latvia

South Korea4 sites
  • KR1035

    Cheonan

  • UA1037

    Gyeongsang

  • KR1032

    Seoul

  • KR1038

    Seoul

Other trials in South Korea

Ukraine4 sites
  • UA1002

    Kyiv

  • UA1019

    Odesa

  • UA1001

    Poltava

  • UA1004

    Ternopil

Other trials in Ukraine

France3 sites
  • FR1041

    Douai

  • FR1017

    Élancourt

  • FR1009

    Nantes

Other trials in France

South Africa3 sites
  • ZA1019

    Cape Town

  • ZA1022

    Randburg

  • ZA1023

    Sandton

Other trials in South Africa

Bulgaria2 sites
  • BG1023

    Targovishte

  • BG1025

    Varna

Other trials in Bulgaria

Canada2 sites
  • CA1036 University of Calgary

    Calgary

  • CA1038

    Toronto

Other trials in Canada

Estonia2 sites
  • EE1007

    Tallinn

  • EE1015

    Viljandi

Other trials in Estonia

Hungary2 sites
  • HU1023

    Budapest

  • HU1020

    Gyula

Other trials in Hungary

United Kingdom2 sites
  • GB1051

    Glasgow

  • GB1047

    Liverpool

Other trials in United Kingdom

About this study

Official title: Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

Being tested
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo
Keywords
paediatric patients
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vortioxetine 10 mg/dayDrug

    Also called Brintellix ®, Lu AA21004

    10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

  • Vortioxetine 20 mg/dayDrug

    Also called Brintellix ®, Lu AA21004

    20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

  • Fluoxetine 20 mg/dayDrug

    20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

  • PlaceboOther

    Encapsulated tablet

Study groups in NCT02709746
Study groupRoleWhat they receive
Vortioxetine 10 mg/dayExperimentalNot described
Receives: Drug: Vortioxetine 10 mg/day
Vortioxetine 20 mg/dayExperimentalNot described
Receives: Drug: Vortioxetine 20 mg/day
Fluoxetine 20 mg/day,Active comparatorNot described
Receives: Drug: Fluoxetine 20 mg/day
PlaceboPlacebo comparatorNot described
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Measured: From Randomization to Week 8

Secondary outcomes (27)
  1. Change in CDRS-R Total Score During Treatment (at Week 2)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.

    Measured: At week 2

  2. Change in CDRS-R Total Score During Treatment (at Week 4)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Measured: At week 4

  3. Change in CDRS-R Total Score During Treatment (at Week 6)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Measured: At week 6

  4. Change in CDRS-R Mood Score

    Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.

    Measured: From randomization to Week 8

  5. Change in CDRS-R Somatic Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.

    Measured: From Randomization to Week 8

  6. Change in CDRS-R Subjective Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.

    Measured: From Randomization to Week 8

  7. Change in CDRS-R Behaviour Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.

    Measured: From Randomization to Week 8

  8. CDRS-R Response

    Children Depression Rating Scale - Response: defined as a >= 50% decrease in CDRS-R total score, calculated as (change from baseline [Randomization])/(baseline value - 17).

    Measured: From Randomization to Week 8

  9. CDRS-R Remission

    Remission is defined as a CDRS-R total score <= 28.

    Measured: From Randomization to Week 8

  10. Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents

    Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

    Measured: From randomization to week 8

  11. Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child

    The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.

    Measured: From randomization to Week 8

  12. Parent Global Assessment-Global Improvement (PGA) Score

    The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).

    Measured: From Randomization to Week 8

  13. Change in Symbol Digit Modalities Test (SDMT)

    The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).

    Measured: From Randomization to Week 8

  14. Change in Clinical Global Impression Severity of Illness (CGI-S) Score

    The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Measured: From Randomization to Week 8

  15. Clinical Global Impression - Global Improvement (CGI-I) Score

    The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

    Measured: From Randomization to Week 8

  16. CGI-S Remission

    Remission defined as CGI-S score of 1 or 2.

    Measured: From Randomization to Week 8

  17. Change in Children's Global Assessment Scale (CGAS) Score

    The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.

    Measured: From Randomization to Week 8

  18. Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to Week 8

  19. Change in PedsQL VAS: Sad or Blue (Sadness) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to Week 8

  20. Change in PedsQL VAS: Angry Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to Week 8

  21. Change in PedsQL VAS: Worry Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to Week 8

  22. Change in PedsQL VAS: Tired (Fatigue) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to week 8

  23. Change in PedsQL VAS: Pain or Hurt Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: From Randomization to Week 8

  24. Change in PedsQL VAS Total Average Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

    Measured: From Randomization to week 8

  25. Change in PedsQL Emotional Distress Summary Average Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

    Measured: From Randomization to week 8

  26. Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores

    PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.

    Measured: From Randomization to Week 8

  27. Change in PQ-LES-Q Overall Score

    PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

    Measured: From Randomization to Week 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2016 (estimated)
  2. Study startMay 2016
  3. Primary completion2 Jul 2019
  4. Study completion30 Jul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
784 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02709746
Sponsor's protocol ID
12710A
Other IDs
2008-005354-20, 2008
Status last verified
Aug 2020
First submitted
11 Mar 2016
Last updated
19 Aug 2020
Data monitoring committee
Yes

Publications

  • Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13.

    PubMed 35033635

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 124 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 124 sites in United States, Russia, Italy, Mexico, Poland and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment (time frame: From Randomization to Week 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02709746, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT02709746 | AzTrials